Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

MLA

Norden, Andrew D., et al. “Phase II Study of Monthly Pasireotide LAR (SOM230C) for Recurrent or Progressive Meningioma.” Neurology, vol. 84, no. 3, Jan. 2015, pp. 280–86. EBSCOhost, https://doi.org/10.1212/WNL.0000000000001153.

APA

Norden, A. D., Ligon, K. L., Hammond, S. N., Muzikansky, A., Reardon, D. A., Kaley, T. J., Batchelor, T. T., Plotkin, S. R., Raizer, J. J., Wong, E. T., Drappatz, J., Lesser, G. J., Haidar, S., Beroukhim, R., Lee, E. Q., Doherty, L., Lafrankie, D., Gaffey, S. C., Gerard, M., … Wen, P. Y. (2015). Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology, 84(3), 280–286. https://doi.org/10.1212/WNL.0000000000001153

Chicago

Norden, Andrew D, Keith L Ligon, Samantha N Hammond, Alona Muzikansky, David A Reardon, Thomas J Kaley, Tracy T Batchelor, et al. 2015. “Phase II Study of Monthly Pasireotide LAR (SOM230C) for Recurrent or Progressive Meningioma.” Neurology 84 (3): 280–86. doi:10.1212/WNL.0000000000001153.